DCPIB

DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC) . DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC50s: 0.14, 0.95, 50.72 μM, respectively) . DCPIB is also a selective blocker of swelling-induced chloride current (ICl, swell), with an IC50 of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels[1][2].

Product Specifications

CAS Number

[82749-70-0]

UNSPSC

12352005

Hazard Statement

H301, H318, H413

Target

Chloride Channel; Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/dcpib.html

Purity

99.83

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CCCOC1=CC2=C(C(C(C3CCCC3)(CCCC)C2)=O)C(Cl)=C1Cl

Molecular Formula

C22H28Cl2O4

Molecular Weight

427.36

Precautions

H301, H318, H413

References & Citations

[1]Lv J, et al. DCPIB, an Inhibitor of Volume-Regulated Anion Channels, Distinctly Modulates K2P Channels. ACS Chem Neurosci. 2019 Apr 17.|[2]Decher N, et al. DCPIB is a novel selective blocker of I (Cl, swell) and prevents swelling-induced shortening of guinea-pig atrial action potential duration. Br J Pharmacol. 2001 Dec;134 (7) :1467-79.|[3]Qingdong Han, et al. DCPIB, a potent volume-regulated anion channel antagonist, attenuates microglia-mediated inflammatory response and neuronal injury following focal cerebral ischemia. Brain Res. 2014 Jan 13;1542:176-85.